Campus: CSU Bakersfield -- February 20, 2004
Valley Fever Vaccine Project Advances
Scientists with the Valley Fever Vaccine Project, administered by California
State University, Bakersfield Foundation, announced today that they
have selected a candidate for a Valley Fever vaccine after four years
of intensified research at five research centers around the country.
The development was outlined today during a meeting of project directors,
one of the scientists involved in the research, U.S. Rep. Bill Thomas
and the CSUB Foundation Board of Directors.
“We have great news,” Dr. Richard Hector, director of the
Valley Fever Vaccine Project, told a gathering of 50 people in the Dezember
Leadership Development Center on the CSUB campus. “A vaccine is
at hand.” Hector’s presentation was interrupted by spontaneous
The project directors announced that as a result of successful experimental
results, including primate trials evaluating the candidate vaccine,
they are at the point of initiating the pharmaceuticaldevelopment, with
the goal of testing the vaccine in humans. As a first step, the project
has recently entered into an agreement with the University of Nebraska
to “develop the fermentation and purification ofthe vaccine under
consideration for the human clinical trials,” Hector said.
“We believe that we have identified the antigens we want to take
forward. The antigens are not the entirety of what constitutes a vaccine,
but they are the critical component. The combination of the research
data plus the recent results from the primate trial brought us to a
decision point. Even though the trial is still in progress, the results
to date are convincing enough to validate our choice of the antigens.
This is very good news."
During the meeting Thomas, R-Bakersfield, chairman of the House Ways
and Means Committee, was recognized by the CSUB Foundation board for
the $750,000 grant providing funding for the project through the Centers
for Disease Control. These funds will be used exclusively for the early
phases of the pharmaceutical development of the vaccine, critical to
achieving the goal of planned human testing.
Also attending the meeting were Dr. George Rutherford of the University
of California, San Francisco, who has been involved with the project
since its inception; Dr. John Galgiani, professor of medicine at the
University of Arizona and founder and director of the Valley Fever Center
for Excellence at the University of Arizona, and one of the five principal
scientists on the project; and Dr. Duane Blume, retired CSUB biology
professor whose feasibility study more than a decade ago lead to the
formation of the Valley Fever Vaccine Project.
Since the beginning of the research project under the auspices of the
CSUB Foundation in 1997, with its initial grant from the California
HealthCare Foundation and an appropriation from the California Legislature,
the researchers have been working towards the goal of moving potential
vaccine candidates from the research phase to clinical trials.
Valley Fever is caused by a fungus, coccidioides immitis, which exists
in the soil in various areas of the American Southwest, northern Mexico
and Central and South America that have arid or semiarid conditions
and hot summers with mild, non-freezing winters.
The disease has been recognized as a significant medical entity since
the 1890s, and its association with the San Joaquin Valley, particularly
Kern County, was realized during the first three decades of the 20th
The Valley Fever Vaccine Project began in 1997 after a major Valley
Fever outbreak from 1991 through 1994 renewed interest in vaccine development.
Members of the Bakersfield business and medical communities formed the
Valley Fever Research Foundation to develop a plan to hasten vaccine
development. They enlisted the Center for Biomedical Research at CSUB
and its director, Duane Blume, to conduct a feasibility study on the
potential for a vaccine. Blume's study concluded that prospects were
excellent and would be greatly enhanced by a collaborative research
program by the five leading scientists in Valley Fever research:
- Dr. Garry Cole, professor and chairman of the Department of Microbiology
at the Medical College of Ohio in Toledo.
- Dr. Rebecca Cox, adjunct professor of microbiology at the University
of Texas Health Science Center and director of the Laboratory of Clinical
Investigation at the Texas Center for Infectious Disease.
- Dr. Theo Kirkland III, assistant director of the microbiology laboratory
and a staff physician at the Veterans Administration Medical Center
in San Diego, a member of the Center of Molecular Genetics at the
University of California, San Diego, and associate professor of pathology
and medicine in residence, Division of Infectious Diseases at UCSD.
- Dr. Demosthenes Pappagianis, professor in the Department of Medical
Microbiology and Immunology at the University of California, Davis
School of Medicine.
CONTACT: Mike Stepanovich, 661/664-2456, email@example.com